Tung M-Y, Mandalia S, Bower M, Gazzard B, Nelson M
St. Stephens Centre, Chelsea and Westminster Hospital, London, UK.
HIV Med. 2005 May;6(3):151-4. doi: 10.1111/j.1468-1293.2005.00279.x.
Tenofovir (TDF) co-administered with didanosine (ddI) 400 mg increases ddI plasma concentrations by up to 60%, raising concerns over toxicity. To limit this interaction, the dosage of ddI may be reduced to 250 mg once daily when co-prescribed with TDF. In this clinical cohort, highly active antiretroviral therapy regimens containing TDF and ddI 250 mg were significantly better tolerated than combinations with TDF and ddI at a dose of 400 mg. Low-dose ddI 250 mg once daily plus TDF as part of antiretroviral therapy was effective.
替诺福韦（TDF）与400毫克去羟肌苷（ddI）联合使用时，会使ddI的血浆浓度提高多达60%，这引发了对毒性的担忧。为限制这种相互作用，当与TDF联合处方时，ddI的剂量可减至每日一次250毫克。在这个临床队列中，含有TDF和250毫克ddI的高效抗逆转录病毒治疗方案的耐受性明显优于含有TDF和400毫克ddI的组合。每日一次250毫克的低剂量ddI加TDF作为抗逆转录病毒治疗的一部分是有效的。
